Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Stephen M Keefe, MD, MSCE

Stephen M Keefe, MD, MSCE

faculty photo
Adjunct Assistant Professor of Medicine
Department: Medicine

Contact information
Merck Research Laboratories
126 E. Lincoln Avenue
Rahway, NJ 07065
Philadelphia, PA 19104
B.S.E.E. (Electrical Engineering)
University of Notre Dame, 1993.
B.A. (Philosophy)
University of Notre Dame, 1993.
Certif. (Post-Baccalaureate Program in Pre-Medical Studies)
Columbia University, 1997.
Pritzker School of Medicine, University of Chicago, 2003.
M.S.C.E. (Clinical Epidemiology & Biostatistics, anticipated)
Perelman School of Medicine, University of Pennsylvania, 2014.
Permanent link
Perelman School of Medicine > Faculty > Search

Selected Publications

Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD: Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 37(7): 1910-7, July 2014.

Ju M, Kao GD, Steinmetz D, Chandrasekaran S, Keefe SM, Guzzo TJ, Christodouleas JP, Hahn SM, Dorsey JF: Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study. Cancer Biology and Therapeutics 15(6): 683-7, June 2014.

Keefe SM, Hennessy M, Gunnarsson O, Mamtani R, Vaughn D, Hoffman-Censits Jean, Nathanson KL, Lal P, Pryma D, Eliasof S, Garmey E, Cohen RB, Haas NB: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab in refractory metastatic renal cell carcinoma - results from the planned interim analysis. American Association of Cancer Research (AACR) 2014 Annual Meeting April 2014 Notes: Oral Abstract Presentation.

Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C, Vapiwala N, Vaughn DJ, Keefe SM, Guzzo T, Malkowicz SB, Christodouleas JP: Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. International Journal of Radiation Oncology, Biology and Physics 88(3), March 2014.

Brose MS, Frenette CT, Keefe SM, Stein SM: Management of sorafenib-related adverse events: a clinician's perspective. Seminars in Oncology Suppl 2: S1-S16, February 2014.

Keefe SM, Heitjan D, Hennessey M, Robinson J, Mykulowicz K, Marshall A, Gunnarsson O, Mamtani R, Vaughn DJ, Hoffman-Censits JH, Nathanson KL, Lal P, Pryma DA, Eliasof S, Garmey EG, Cohen RB, Haas NB: Interim Results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 (Cerulean Pharma, Inc., Cambridge, MA, USA) with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). 2014 GU Cancers Symposium ASCO Supplement, February 2014.

Keefe SM, Rosen MA, Robinson J, McGibney K, Marshall A, Mamtani R, Vaughn DJ, O'Dwyer PJ, Haas NB, Pryma DA: Results of a feasibility study of I-124 girentuximab (Wilex AB) in metastatic clear cell renal cell carcinoma (m ccRCC). 2014 GU Cancers Symposium ASCO Supplement, February 2014.

Keefe SM, Nathanson KL, Rathmell WK: Molecular biology of renal cell carcinoma. Seminars in Oncology 40(4): 421-8, August 2013.

Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ: Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int 112(1): 13-25, July 2013.

Keefe SM, Cohen R, Eliasof S, Garmey EG, Mykulowicz KM, Pryma D, Haas NB: A Phase Ib-IIa Study Evaluating the Nanopharmaceutical CRLX101 in Combination with Bevacizumab in the Treatment of Patients with Advanced Renal Cell Carcinoma (NCT01625936). 2013 Association of American Cancer Research April 2013.

back to top
Last updated: 04/24/2015
The Trustees of the University of Pennsylvania